Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03851094 · ClinicalTrials.gov registry record · NA
Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients
A NA study, sponsored by ResMed.
- Completed
- Registry status
- NA
- Development phase
- 166
- Enrollment target
NCT03851094: Completed NA study, sponsored by ResMed.
NCT03851094 is a NA study that has completed, run by ResMed. The registered enrollment target is 166 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03851094, a NA study, has completed, sponsored by ResMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 166 participants
- Enrollment target
Study Summary
This is a prospective, randomized, open-label study to evaluate effectiveness of applying financial and social incentives via a smartphone-based app in helping participants achieve adherence to PAP therapy.
Primary Outcome
Average nightly CPAP use for the 90 day time frame.
Interventions
- BEHAVIORAL Wellth app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2020-08-16 |
| Phase | NA |
What the finished NCT03851094 record still lists
NCT03851094 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Wellth app is the first listed.
NCT03851094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03851094 about?
NCT03851094 is a clinical study titled "Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients". This is a prospective, randomized, open-label study to evaluate effectiveness of applying financial and social incentives via a smartphone-based app in helping participants achieve adherence to PAP therapy.
What is the current status of trial NCT03851094?
This trial is currently completed. It is a NA study. The enrollment target is 166 participants. The study started on 2019-03-11. Estimated completion is 2020-08-16.
What interventions are being tested in trial NCT03851094?
The interventions under investigation include: Wellth app (BEHAVIORAL).
Who is sponsoring clinical trial NCT03851094?
This trial is sponsored by ResMed, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03851094's enrollment target sits among peer trials
166 625th of 2000 higher than 1,375 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI